195 related articles for article (PubMed ID: 37318478)
21. Mid-term results of intralesional extended curettage, cauterization, and polymethylmethacrylate cementation in the treatment of giant cell tumor of bone: A retrospective case series.
Şirin E; Akgülle AH; Topkar OM; Sofulu Ö; Baykan SE; Erol B
Acta Orthop Traumatol Turc; 2020 Sep; 54(5):524-529. PubMed ID: 33155564
[TBL] [Abstract][Full Text] [Related]
22. Giant cell tumour of bone in the denosumab era.
van der Heijden L; Dijkstra PDS; Blay JY; Gelderblom H
Eur J Cancer; 2017 May; 77():75-83. PubMed ID: 28365529
[TBL] [Abstract][Full Text] [Related]
23. [Clinical studies on effect of bone cement filling on articular cartilage of the knee after curettage of giant cell tumor].
Cao W; Ye Z; Lin N; Liu M
Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi; 2014 Dec; 28(12):1459-63. PubMed ID: 25826886
[TBL] [Abstract][Full Text] [Related]
24. Efficacy of denosumab in joint preservation for patients with giant cell tumour of the bone.
Traub F; Singh J; Dickson BC; Leung S; Mohankumar R; Blackstein ME; Razak AR; Griffin AM; Ferguson PC; Wunder JS
Eur J Cancer; 2016 May; 59():1-12. PubMed ID: 26990281
[TBL] [Abstract][Full Text] [Related]
25. Recurrent giant cell tumour of the distal ulna after en bloc resection with preoperative denosumab use.
Fujihara N; Hamada S; Yoshida M; Tsukushi S
BMJ Case Rep; 2021 Nov; 14(11):. PubMed ID: 34764115
[TBL] [Abstract][Full Text] [Related]
26. Risk factors of fracture following curettage for bone giant cell tumors of the extremities.
Tsukamoto S; Mavrogenis AF; Akahane M; Honoki K; Kido A; Tanaka Y; Donati DM; Errani C
BMC Musculoskelet Disord; 2022 May; 23(1):477. PubMed ID: 35590280
[TBL] [Abstract][Full Text] [Related]
27. Utility of intraoperative magnetic resonance imaging for giant cell tumor of bone after denosumab treatment: a pilot study.
Furuta T; Kubo T; Sakuda T; Saito T; Kurisu K; Muragaki Y; Adachi N
Acta Radiol; 2022 Feb; 63(2):176-181. PubMed ID: 33517664
[TBL] [Abstract][Full Text] [Related]
28. Denosumab in giant cell tumour of bone in the pelvis and sacrum: Long-term therapy or bone resection?
Sambri A; Medellin MR; Errani C; Campanacci L; Fujiwara T; Donati D; Parry M; Grimer R
J Orthop Sci; 2020 May; 25(3):513-519. PubMed ID: 31155442
[TBL] [Abstract][Full Text] [Related]
29. Neoadjuvant denosumab: its role and results in operable cases of giant cell tumour of bone.
Puri A; Gulia A; Hegde P; Verma V; Rekhi B
Bone Joint J; 2019 Feb; 101-B(2):170-177. PubMed ID: 30700112
[TBL] [Abstract][Full Text] [Related]
30. Does curettage-cement packing for treating giant cell tumors at the knee lead to osteoarthritis?
Caubère A; Harrosch S; Fioravanti M; Curvale G; Rochwerger A; Mattei JC
Orthop Traumatol Surg Res; 2017 Nov; 103(7):1075-1079. PubMed ID: 28782699
[TBL] [Abstract][Full Text] [Related]
31. Preoperative denosumab treatment in patients with giant cell bone tumors in limbs: A retrospective study using propensity score matching.
Huang Y; Xu M; Wang B; Zhao Z; Lin T; Huang G; Yin J; Xie X; Shen J; Zou C
Cancer Med; 2023 Jun; 12(11):12041-12049. PubMed ID: 37212474
[TBL] [Abstract][Full Text] [Related]
32. Updated concepts in treatment of giant cell tumor of bone.
van der Heijden L; Lipplaa A; van Langevelde K; Bovée JVMG; van de Sande MAJ; Gelderblom H
Curr Opin Oncol; 2022 Jul; 34(4):371-378. PubMed ID: 35837707
[TBL] [Abstract][Full Text] [Related]
33. An eggshell-like mineralized recurrent lesion in the popliteal region after treatment of giant cell tumor of the bone with denosumab.
Akaike K; Suehara Y; Takagi T; Kaneko K; Saito T
Skeletal Radiol; 2014 Dec; 43(12):1767-72. PubMed ID: 25052539
[TBL] [Abstract][Full Text] [Related]
34. Denosumab in patients with giant-cell tumour of bone: a multicentre, open-label, phase 2 study.
Chawla S; Blay JY; Rutkowski P; Le Cesne A; Reichardt P; Gelderblom H; Grimer RJ; Choy E; Skubitz K; Seeger L; Schuetze SM; Henshaw R; Dai T; Jandial D; Palmerini E
Lancet Oncol; 2019 Dec; 20(12):1719-1729. PubMed ID: 31704134
[TBL] [Abstract][Full Text] [Related]
35. Is Treatment with Denosumab Associated with Local Recurrence in Patients with Giant Cell Tumor of Bone Treated with Curettage? A Systematic Review.
Tsukamoto S; Tanaka Y; Mavrogenis AF; Kido A; Kawaguchi M; Errani C
Clin Orthop Relat Res; 2020 May; 478(5):1076-1085. PubMed ID: 31794487
[TBL] [Abstract][Full Text] [Related]
36. A randomized phase III trial of denosumab before curettage for giant cell tumor of bone: Japan Clinical Oncology Group Study JCOG1610.
Urakawa H; Mizusawa J; Tanaka K; Eba J; Hiraga H; Kawai A; Nishida Y; Hosaka M; Iwamoto Y; Fukuda H; Ozaki T
Jpn J Clin Oncol; 2019 Apr; 49(4):379-382. PubMed ID: 30796832
[TBL] [Abstract][Full Text] [Related]
37. Giant cell tumour of bone.
Aoude A; Nikomarov D; Perera JR; Ibe IK; Griffin AM; Tsoi KM; Ferguson PC; Wunder JS
Bone Joint J; 2023 May; 105-B(5):559-567. PubMed ID: 37121582
[TBL] [Abstract][Full Text] [Related]
38. Current concepts in the treatment of giant cell tumour of bone.
van der Heijden L; Dijkstra S; van de Sande M; Gelderblom H
Curr Opin Oncol; 2020 Jul; 32(4):332-338. PubMed ID: 32541321
[TBL] [Abstract][Full Text] [Related]
39. Soft tissue extension increases the risk of local recurrence after curettage with adjuvants for giant-cell tumor of the long bones.
van der Heijden L; van de Sande MA; Dijkstra PD
Acta Orthop; 2012 Aug; 83(4):401-5. PubMed ID: 22880716
[TBL] [Abstract][Full Text] [Related]
40. [Denosumab may be a supplement to the surgical treatment of giant cell tumours of bone].
Sørensen AL; Hansen RL; Jørgensen PH
Ugeskr Laeger; 2016 Sep; 178(36):. PubMed ID: 27593237
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
